Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Study Number: WF-1801
Study Summary:
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.
Status: Open
Study Coordinator(s)
- Courtney, 309-243-3660 cbrown@illinoiscancercare.com
- Kelsey, 309-243-3618 kfay@illinoiscancercare.com
- Erica, 309-243-3626 eraynor@illinoiscancercare.com
